The University of Toledo

Cognitive Pharmaceuticals/
Mithridion, Inc.

Cognitive Pharmaceuticals, Ltd. and Mithridion, Inc. have merged forces to develop drugs for Alzheimer’s disease and other serious Central Nervous System disorders. As the surviving entity, Mithridion, Inc. will maintain its headquarters in Madison, WI while the early drug discovery and clinical drug development operations will be located in Toledo, OH. Upon completion of the merger, Mithridion announced the closing of a Series B round in the amount of $2.3 million, which will be used to commence clinical trials of Mithridion’s first drug candidate, MCD-386.

• Mithridion’s IND for MCD-386 cleared on July 2, 2008, and the company commenced a Phase I single dose escalation study in normal volunteers on July 9, 2008.

The Turning Point, LLC

A manufacturing and marketing firm that produces a state-of-the-art golf exercise and therapeutic device.

• Successful manufacturing partnership established in 2007.
• Now developing phase II prototype Product introduction expected 2nd Q 2008

A manufacturing and marketing company that develops thin-film silicon based photovoltaic products and manufacturing equipment for high-throughput production of flexible and lightweight photovoltaic modules at low cost.

• Xunlight has completed a $7M Series A financing and a $22M and $11M Series B financing to build a roll-to-roll pilot production line. 

Spinal Designs

A marketing firm that provides products and services to orthopaedic surgeons.

• Virtual Company with success in sublicensing technologies

"Amedical device company developing and commercializing a non-invasive glucose measurement technology for use by persons with diabetes.  The consumer ready product is anticipated to operate in similar fashion to a pair of binoculars." 

• The company is working to secure $1.7M of Series A financing
• Preparing for pilot human clinical studies.

Suganit Systems, Inc.

A start-up company involved in the research and development of renewable and clean energy with a focus on ethanol production from biomass

• Still perfecting technology
• Discussions with major multi-national partners progressing

A start-up focused on developing a revolutionary approach for the treatment of threatening clinical conditions. The company’s primary product, pegylated albumin, is a therapeutic colloid-type blood volume expander agent that is superior to human serum albumin.

• Recipient of a $50,000 Ignite Grant from the Regional Growth Partnership 

A technology-based startup company focused on developing Cd-Te thin-film photovoltaics on polyimide substrates.

Gamma Spine is creating a posterior lumbar disk replacement with a novel design.  Through mathematical testing, the company has created a device that once inserted can be contracted during surgery and expanded, allowing surgery to be completed with less risk for "spinal nerve root" damage.